Cardiovascular Morbidity Clinical Trial
— InvestiCATOfficial title:
Investigating Cardiovascular Adverse Events Related to Cancer Treatment: a Study of Extreme Toxicity Using Induced Pluripotent Stem Cells
NCT number | NCT03199300 |
Other study ID # | 201700454 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | December 12, 2017 |
Est. completion date | January 2025 |
Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown. Unraveling extreme cardiovascular toxic responses in cancer patients may help understand the pathophysiology of cardiovascular toxicity of these agents and help in understanding the more subtle, long-term cardiovascular side effects that affect a larger part of cancer survivors. With induced pluripotent stem cells we will obtain patient-derived cells to recapitulate and mimic and study pathological (cardiovascular) responses and (cardiovascular) toxicity in vitro.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | January 2025 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all of these criteria: 1. any proven cancer treated with curative intent; 2. age = 18 and = 50 years; 3. able to comply with the protocol; 4. signed written informed consent. There are specific inclusion criteria for every subject group: - severe toxicity during 1 to 3 cycles of anthracyclines; - = 3 months after end of cancer treatment which included the maximum tolerable dose of anthracyclines without (severe) toxicity; - severe toxicity within 1 to 6 cycles of trastuzumab; - = 3 months after end of cancer treatment which included a year of trastuzumab without (severe) toxicity. - severe toxicity during 1 to 3 cycles of cisplatin; - = 1 year after end of cancer treatment which included high-dose cisplatin without toxicity; - severe toxicity during 1 to 3 cycles of bleomycin; - = 1 year after end of cancer treatment which included high-dose bleomycin without toxicity. Severe toxicity is defined as any of grade 3 - 4 toxicity according to CTCAE 4.03. A potential subject who meets any of the following exclusion criteria will be excluded from participation in this study: 1. history of cardiovascular disease prior to start of cancer treatment, as evidenced by any of the following: symptomatic or treated cardiovascular disease prior to start of cancer treatment; LVEF < 55% at any performed MUGA scan or echocardiography prior to start of cancer treatment; 2. any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol, or insufficient understanding of the Dutch language; 3. any contraindication for skin biopsy, including: extensive skin disorder precluding biopsy of unaffected skin; known allergy to local anaesthetics; use of anticoagulants and INR > 3; 4. pregnant or lactating female. Furthermore, there are specific exclusion criteria for the control groups: 5. history of cardiovascular disease during or after cancer treatment, as evidenced by any of the following: any symptomatic or treated cardiovascular disease; LVEF < 55% at any performed MUGA scan or echocardiography. |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Center Groningen | Groningen |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison between iPSC-derived cells | Comparison between iPSC-derived cells from toxicity cases and controls, for each of the four different agents. | 3 years | |
Secondary | Correlate the findings from the iPSC-derived cells with the clinical phenotype of cardiovascular toxicity | Correlate the findings from the iPSC-derived cells with the clinical phenotype of (cardiovascular) toxicity, assessed by circulating biomarkers and cardiac or vascular imaging. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
Completed |
NCT02359370 -
The Effects of Lidocaine and Magnesium Sulphate on the Attenuation of the Hemodynamic Response to Tracheal Intubation
|
Phase 4 | |
Not yet recruiting |
NCT05435898 -
Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese
|
||
Recruiting |
NCT04624503 -
Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19
|
||
Recruiting |
NCT04428827 -
Outcome of Patients With Primary Aldosteronism
|
||
Completed |
NCT04609332 -
Endothelial Damage and Angiogenesis Biomarkers During COVID-19
|
||
Completed |
NCT04132531 -
Effect of Weight Loss Surgery on Stem Cells.
|
||
Completed |
NCT05057650 -
Help Everyone Assess Risk Today: LEnten Nutrition Study (HEART-LENS)
|
N/A | |
Recruiting |
NCT05432856 -
Impact of Metabolic Health Patterns And Breast Cancer Over Time in Women
|
N/A | |
Completed |
NCT04189497 -
Development of a Prognostic Tool for the Stratification of Cardiovascular Risk in Patients With Ischemic Stroke
|
||
Not yet recruiting |
NCT05802121 -
Akkermansia Muciniphilia and Metabolic Side Effects of ADT
|
Early Phase 1 | |
Recruiting |
NCT01914783 -
Experimental Exposure to Air Pollutants and Sympathetic Nerve Activity in Human Subjects
|
N/A | |
Recruiting |
NCT05645978 -
Association of Obesity and Cardiovascular Outcomes in Patients With Pacemaker
|
||
Recruiting |
NCT05645965 -
Association of Obesity and Cardiovascular Outcomes in Patients With Implantable Cardioverter-defibrillator (ICD)
|
||
Recruiting |
NCT05645939 -
Association of Obesity and Cardiovascular Outcomes in Hypertrophic Cardiomyopathy
|
||
Recruiting |
NCT05645952 -
Association of Obesity and Cardiovascular Outcomes in Dilated Cardiomyopathy
|
||
Completed |
NCT05293379 -
Prospective, Multicenter Study Assessing a Screening Campaign for Cardiovascular Diseases Risk Factors During SARS-CoV-2 Epidemic
|
||
Completed |
NCT03256175 -
The Effect of Peri-percutaneous Coronary Intervention Oxygenation on Myocardial Protection & Cardiovascular Fitness
|
N/A | |
Enrolling by invitation |
NCT03451929 -
Kidney Function and Cardiovascular Events: Cohort Study in General Population
|
N/A | |
Completed |
NCT04717986 -
Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI)
|
N/A |